Topics

Glioblastoma | Treatment | Tumor treating fields

Home > Publications > Topics > Glioblastoma > Treatment > Tumor treating fields

2024

Mikic N, Gentilal N, Cao F, Lok E, Wong ET, Ballo M, Glas M, Miranda PC, Thielscher A, Korshoej AR.
Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose-response relationships.
Neurooncol Adv. 2024 Mar 2;6(1):vdae032. doi: 10.1093/noajnl/vdae032. PMID: 38560348. Review. ˍ

*Wang J, Du Q, Chen J, Liu J, Gu Z, Wang X, Zhang A, Gao S, Shao A, Zhang J, Wang Y.
Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors.
Front Oncol. 2024 Mar 20;14:1345190. doi: 10.3389/fonc.2024.1345190. PMID: 38571508. Observational study. ˍ

Xiang Y, Chen Y, Xu Z, Zhou S, Qin Z, Chen L, Xiao D, Liu S.
Real-world cost-effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04662-x. PMID: 38563851. Observational study˰ ˍ

Lan J, Liu Y, Chen J, Liu H, Feng Y, Liu J, Chen L.
Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma.
CNS Neurosci Ther. 2024 May 7;30(5):e14720. doi: 10.1111/cns.14720. PMID: 38715344. Review. ˍ

Goldlust SA, Singer S, Cappello LA, AlMekkawi AK, Lee KD, Ingenito AC, Lewis BE, Nyirenda T, Azmi H, Kaptain GJ.
Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma.
Neurooncol Adv. 2024 Jul 29;6(1):vdae129. doi: 10.1093/noajnl/vdae129. PMID: 39211521. Interventional study.ˍ

*Pan J, Eskandar T, Ahmed Z, Agrawal DK.
Biophysical and Biological Mechanisms of Tumor Treating Fields in Glioblastoma.
J Cancer Sci Clin Ther. 2024 Aug 19;8(3):265-270. doi: 10.26502/jcsct.5079249. PMID: 39364266. Perspective. ˍ

Biedermann GB, Merrifield K, Lustgarten L.
Case report: Safety of Tumor Treating Fields therapy with an implantable cardiac pacemaker in a patient with glioblastoma.
Front Oncol. 2024 Aug 22;14:1441146. doi: 10.3389/fonc.2024.1441146. PMID: 39239269. Case report. ˍ

Mergen E, Landrock S, Chizzali B.
Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma.
Case Rep Oncol. 2024 Sep 23;17(1):1056-1062. doi: 10.1159/000540669. PMID: 39474554. Case report. ˍ

Khagi S, Kotecha R, Gatson NTN, Jeyapalan S, Abdullah HI, Avgeropoulos NG, Batzianouli ET, Giladi M, Lustgarten L, Goldlust SA.
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.
Oncologist. 2024 Oct 14:oyae227. doi: 10.1093/oncolo/oyae227. PMID: 39401002. Review. ˍ

Cai Z, Yang Z, Wang Y, Li Y, Zhao H, Zhao H, Yang X, Wang C, Meng T, Tong X, Zheng H, He Z, Niu C, Yang J, Chen F, Yang Z, Zou Z, Li W.
Tumor treating induced fields: a new treatment option for patients with glioblastoma.
Front Neurol. 2024 Oct 17;15:1413236. doi: 10.3389/fneur.2024.1413236. PMID: 39484048. Laboratory investigation. ˍ

2025

Shah S, Nag A, Lucke-Wold B.
Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.
Clin Transl Oncol. 2025 Feb 1. doi: 10.1007/s12094-025-03849-6. PMID: 39893330. Review˰ ˍ

Li J, Tao J, Lu H, Fan X, Wang Z, Wang Y, Wang X, Yan W, You Y, Cao Y, Zhang J.
Concurrent Tumor-Treating Fields and Chemoradiotherapy: Outcomes in Grade 4 Glioma Patients.
Clin Med Insights Oncol. 2025 Feb 24;19:11795549251315579. doi: 10.1177/11795549251315579. PMID: 40007556. Observational study. ˍ

*Fukami S, Nagai K, Onodera S, Saito Y, Akimoto J, Kohno M.
Photodynamic therapy and tumor-treating fields therapy for newly diagnosed glioblastoma.
Front Oncol. 2025 Feb 28;15:1556669. doi: 10.3389/fonc.2025.1556669. PMID: 40094018. Observational study. ˍ

Ruella ME, Caffaratti G, Del Pont FM, Muggeri A, Yorio F, Mormandi R, Cervio A.
Ependymal invasion in High-Grade Glioma. Impact on surgical, functional outcomes, and survival rates. Experience in a Latin-American center.
Neurosurg Rev. 2025 Mar 7;48(1):286. doi: 10.1007/s10143-025-03445-w. PMID: 40050499. Observational study˰ ˍ

*Takido Y, Ohka F, Deguchi S, Motomura K, Mitsuya K, Aoki K, Shiba Y, Takeuchi K, Nagata Y, Yamaguchi J, Kibe Y, Fuse Y, Maeda S, Shimizu H, Saito R.
Distant parenchymal recurrence during long-term use of TTFields treatment for glioblastoma.
Int J Clin Oncol. 2025 May 22. doi: 10.1007/s10147-025-02775-5. PMID: 40404987. Observational study. ˍ

*Dhingra S, Koshy M, Korpics M.
Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis.
J Cancer Res Clin Oncol. 2025 Jun 2;151(6):179. doi: 10.1007/s00432-025-06171-4. PMID: 40455099. Observational study. ˍ

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

Deshors P, Kheil Z, Ligat L, Gouazé-Andersson V, Cohen-Jonathan Moyal E.
FGFR inhibition as a new therapeutic strategy to sensitize glioblastoma stem cells to tumor treating fields.
Cell Death Discov. 2025 Jun 4;11(1):265. doi: 10.1038/s41420-025-02542-5. PMID: 40467542. Laboratory investigation. ˍ

Crompton DJ, Kern S, Bogan A, Do B, Vora S, Quinones-Hinojosa A, Burns T, Sherman W, Sener UT, Porter AB, Brown P, Laack N, Story MD, Peterson J, Breen WG, Trifiletti DM.
Tumor treating fields utilization and efficacy for glioblastoma at a large multicenter academic practice.
J Clin Neurosci. 2025 Jun 16;138:111395. doi: 10.1016/j.jocn.2025.111395? PMID: 40527221. Observational study˰ ˍ

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

Serventi JN, Newton HB.
Tumor Treating Fields: An Innovative Therapy for Glioblastoma and Other Solid Tumors.
J Adv Pract Oncol. 2025 Sep 1;16(5):181-191. doi: 10.6004/jadpro.2025.16.5.3. PMID: 41041265. Review. ˍ

Mikic N, Lukacova S, Skjøth-Rasmussen J, Poulsen FR, Hauerberg J, Laursen RJ, Ettrup KS, Møller S, Haslund CA, Dahlrot RH, Cortnum SOS, Sindby AK, Von Oettingen G, Valentin JB, Solheim O, Solheim TS, Sørensen JCH, Wong ET, Korshøj AR.
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.
Neurooncol Adv. 2025 Nov 20;7(1):vdaf245. doi: 10.1093/noajnl/vdaf245. PMID: 41473750. Interventional study. ˍ

2026

Li S, Lai M, Chen L, Zhou Y, Li J, Ye M, Ai R, Wang L, Zhang Y, Cai L.
Pineal region germ cell tumors with secondary glioblastoma: A case report of long-term survival using chemoradiotherapy combined with TTFields.
Neurooncol Adv. 2026 Apr 8;8(1):vdaf141. doi: 10.1093/noajnl/vdaf141. PMID: 41969429. ˍ

Abuliezi N, Sun Y, Zhao J, Qu X, Wu Y, Liao T, Kuerban G, Dun X, Wu Q.
Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis.
Front Med (Lausanne). 2026 May 8;13:1812119. doi: 10.3389/fmed.2026.1812119. PMID: 42180742. ˍ

Limon D, Bokstein F, Blumenthal DT, Ram Z, Grossman R.
Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma.
Neurooncol Adv. 2026 Apr 24;8(1):vdag106. doi: 10.1093/noajnl/vdag106. PMID: 42239656. Trial registration ID: NCT03869242. ˍ

Zhu W, Rao J, Hu G, Wang R, Luo X, Li Q.
Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkers.
Neurooncol Adv. 2026 Jul 23;8(1):vdag194. doi: 10.1093/noajnl/vdag194. PMID: 42630691. ˍ